-

Cybin to Present at the Jefferies London Healthcare Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present virtually at the Jefferies London Healthcare Conference being held virtually November 18-19, 2021.

Mr. Drysdale’s presentation will be available on demand beginning on Thursday, November 18, 2021 at 8:00 a.m. GMT/3:00 a.m. ET through Friday, November 19, 2021 at 5:00pm GMT/12:00pm ET. To view the presentation, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Contacts

Investor & Media:

Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

Tim Regan/Scott Eckstein
KCSA Strategic Communications
cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

Industry:

Cybin Inc.

NEO:CYBN
Release Summary
Cybin to Present at the Jefferies London Healthcare Conference
Release Versions
English

Contacts

Investor & Media:

Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

Tim Regan/Scott Eckstein
KCSA Strategic Communications
cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

More News From Cybin Inc.

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq

BOSTON & TORONTO--(BUSINESS WIRE)--Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a...

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the “ATM Program”) to allow Cybin to issue and sell up to US$100,000,000 of common shares in the capital of the Company (the “Shares”) from treasury to the pu...

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares will cease trading on the NYSE American at market close...
Back to Newsroom